Arvind Chavali

Lockstep with regulatory guidance on conducting trials amid crisis, here are four key actions sponsors can take to minimize disruptions.

Biopharmaceutical sponsors should make urgent decisions now to plan for continued clinical research in the coming months.

FDA commissioner Scott Gottlieb criticized pharmaceutical companies and clinical research organizations for being slow to adapt innovations in clinical research, claiming that the business model adopted just isn’t compatible with the kind of changes that certain innovations can enable.